HomeNYSE:NVS

NYSE:NVS

Novartis Poised for Growth in 2024 with Robust Portfolio and Pipeline

Novartis Poised for Growth in 2024 with Robust Portfolio and Pipeline

January 18, 2024

Novartis Completes Spin-off of Sandoz, Reaffirms Annual Outlook

Novartis Completes Spin-off of Sandoz, Reaffirms Annual Outlook

October 4, 2023

Novartis Reports Positive Results for Kidney Disease Medication

Novartis Reports Positive Results for Kidney Disease Medication

October 3, 2023

Novartis’ Sandoz Receives EC Approval for Tysabri Biosimilar

Novartis’ Sandoz Receives EC Approval for Tysabri Biosimilar

September 26, 2023

Novartis Shareholders Approve Sandoz Separation

Novartis Shareholders Approve Sandoz Separation

September 18, 2023